Rochester Clinical Research is currently enrolling adults in a new smoking cessation research study. This trial is designed to evaluate new investigational approaches that could help people successfully quit smoking for good.
Recently Quit Smoking Study
Age Range:
18 to 75
Gender:
Male and Female
Location:
Rochester, New York
About the Study
Every cigarette contains a deadly mix of 7,000 chemicals, including hundreds that are harmful and about 70 known to cause cancer. According to the CDC, tobacco use causes more than 480,000 deaths in the U.S. each year — including 41,000 from secondhand smoke exposure.
If you’ve recently quit smoking or are ready to quit soon, you may be eligible to join a research study to help people stay smoke-free for good.
Rochester Clinical Research is currently enrolling adults in a research study assessing if individuals who recently quit, or willing to quit within a week of their first visit decrease their risk of relapse to cigarette smoking in adults who recently quit. The study will last approximately 34 weeks with 10 visits to our office and 6 “zoom” visits. There is a 33% chance of placebo.
Qualifications
You may qualify if you:
- You may qualify if you:
- Are between 18 and 75 years old
- Have smoked more than 10 cigarettes per day before quitting
- Have recently quit smoking or are willing to quit within one week of your first visit
- Are willing to attend all study visits
Please note, other conditions may apply.
FEATURED STUDIES
Researchers are studying an investigational medication to see how effective it may be as a potential weight reduction treatment. If […]
Adults 18 years and older may qualify for a study evaluating investigational treatment options for diabetic peripheral neuropathic pain (DPNP), […]
Adults 18 years and older may qualify for a study evaluating an investigational oral study medication for elevated lipoprotein(a) [Lp(a)], […]
Adults living with obesity or overweight who do not have type 2 diabetes may qualify for a research study evaluating […]
Adults living with obesity or overweight who do not have type 2 diabetes may qualify for a research study evaluating […]
Adults who are overweight or obese and currently using semaglutide (Ozempic®/Wegovy®) or tirzepatide (Mounjaro®/Zepbound®) may qualify for a research study […]